A B S T R A C T
positive list system was the first to be undertaken in 2007 [5] . New drugs began to be listed for reimbursement after economic evaluations and price negotiations, and a plan for the reevaluation of listed drugs according to an economic evaluation was announced in 2007.
First, among 20,564 items listed as of February 2005, about 4000 items that had never been produced or prescribed since their listing were delisted. The remaining, about 16,000 items, became the target of reevaluation.
Although there were several early controversies surrounding the new drug listing system according to an economic evaluation, such as the lack of local clinical data and/or long-term outcomes data, the system eventually gained some stability [6] . In contrast, the reevaluation of listed drugs has not gone smoothly because of conflicts among stakeholders, including consumer groups, payer groups, subscriber groups, civic groups, and pharmaceutical companies, and the government's inexperience in megaproject management.
In the Korean context, a reevaluation for listed drugs is a practical policy instrument that can greatly contribute to the rationalization of drug expenditures. In addition, its impact would be substantial because it would affect the listing and prices of new drugs, as the listed drugs may become the comparators for new drugs in the economic evaluation.
The purpose of this article was to review the decision-making process, implementation, and implications of the Korean delisting policy and suggest various recommendations, thereby setting a good example for other countries that may be considering a delisting policy.
Reevaluation of Listed Drugs

Original plan
The initial reevaluation plan for listed drugs announced in 2007 by the MOHW started with a pilot evaluation of hyperlipidemia and migraine drugs [7, 8] . These two efficacy groups were selected for the pilot evaluation based on precedents in other countries and because they minimize the confusion of the reimbursement drug list because they are not for the treatment of acute and severe diseases and have neither too big nor too small a market share. This was followed by a formal evaluation involving six efficacy groups, including hypertension drugs, in 2008 [9] . Last, the continuous evaluations for 49 efficacy groups were scheduled for completion by 2011. The efficacy group was classified on the basis of consultation with medical professions and review of literature by the Health Insurance Review and Assessment Service (HIRA), a governmental agency for reviewing the adequacy of claims from medical institutions and supporting various tasks related to health-care management that the government performs. Prioritization of evaluation of 49 efficacy groups was based on the amount claimed for reimbursement and expert opinions [9] . The MOHW governed the overall project, and HIRA was engaged at a working level.
The decision-making process in a pilot evaluation is shown in Figure 1 . In this process, after the MOHW announces the evaluation target groups, HIRA reviews the documents submitted by pharmaceutical companies, evaluates the clinical usefulness, and performs cost-effectiveness analyses of the drugs independently of the data submitted by the pharmaceutical companies. While this process had been carried out by HIRA in the pilot evaluation, the formal evaluation projects were performed by independent research teams in academia selected through competition. Then, after passing through a process in which pharmaceutical companies can give their opinions about the evaluation results, the Drug Reimbursement Evaluation Committee (DREC), the consultative body established in HIRA that makes decisions regarding new drug listings as well as prices of new health technology, reviews the result. Finally, the Health Insurance Policy Review Committee (HIPRC) of the MOHW, an affiliated organization set up for decision making as regards important health insurance policies, confirms and announces the overall results, such as the drugs to be delisted/retained on the reimbursement list [10] (Table 2) . Although the pilot evaluation greatly lagged behind its planned schedule 1. Introduction of a positive list system and drug price negotiation system
• List new drugs evaluated as superior therapeutically and economically only to maximize cost-effectiveness.
• Introduce a negotiation process for new drug pricing between pharmaceutical companies and the National Health Insurance Corporation.
• Fix generic drug prices at a certain percentage of the price of a newly negotiated drug with the same ingredients.
• Reorganize the drugs listed before the DERP enforcement: analyze the cost-effectiveness of drugs according to efficacy groups for 5 years from 2007 to 2011 and delist or adjust the prices of non-cost-effective drugs. 2. Management of drug price listed for reimbursement
• Adjust drug prices with expired patents when the first generic drug with the same ingredients is listed.
• Adjust drug prices through renegotiation if sales exceed the volume agreed upon in advance or if reimbursement scopes are extended.
• Give economic incentives to medical institutions purchasing drugs at lower prices in the transparent route.
Management of drug utilization
• Reduce the volume of prescriptions with the cooperation of medical professionals.
• Tighten up assessments regarding the proper use of drugs.
-Extend the assessment scope, including the prescription rate per certain period of time, the proportion of expensive drugs among prescriptions, and the drug cost per medication day, and open the assessment results to the public. -Monitor institutions prescribing drugs excessively, reinforce education of medical professionals about proper drug use, and consider financial incentives. 4. Improvement of drug quality and transparency in distribution channels
• Increase the reliability of bioequivalence tests of generic drugs and expand test targets.
• Improve the management of product quality and control the manufacturing facilities adequately through the KGMP*.
• Strengthen follow-up testing of drugs: Cancel the approval of drugs if bioequivalence data that pharmaceutical companies are supposed to submit regularly are not submitted after approval.
• Build a system for accumulating and analyzing information about production and supply systematically.
• Upgrade the drug bar code system and use an electronic card dedicated for drug purchases for the efficient management of the distribution of drugs and making the drug trade transparent.
* Korea Good Manufacturing Practice: Regulation for quality assurance such as efficacy, safety, and stability from manufacturing to sales.
because of strong opposition from relevant stakeholders with a large market size of hyperlipidemia drugs, 4 items among 321 were delisted and the prices of 124 items were reduced by 15.2% according to the evaluation results.
In the hypertension drug evaluation process that commenced in July 2009, the specific framework of the reevaluation procedure that could be applied to other efficacy groups in the future was developed on the basis of lessons from the pilot evaluation and a discussion involving the MOHW, HIRA, medical professions, pharmaceutical industry, and those in related academia (Fig. 2) .
First, essential drugs including ban-on-delisting drugs, orphan drugs, emergency drugs, and drugs without any alternatives are to remain on the reimbursement list without any consideration of their effectiveness or cost. Ban-on-delisting drugs are low-priced but indispensable drugs designated by the MOHW for the purpose of preventing pharmaceutical companies from halting their supply because of the nonprofitability of their production. Orphan drugs are drugs for diseases afflicting fewer than 20,000 patients and for which no other proper treatments or alternative medicines exist.
In the second step, drugs are categorized into two groupsmajor and minor disease drugs-on the basis of the relative prevalence rate, the social burden, and the impact of the disease on the insurance budget. Minor disease drugs can remain on the reimbursement list regardless of the cost once they are recognized as clinically useful, because the number of drug items for minor diseases is very small and they cannot be compared with major disease drugs by the same indicators, whereas major disease drugs are subject to subsequent steps. For example, there are two disease codes in hypertension: general hypertension and pulmonary hypertension. Of the two, general hypertension, which is more burdensome socially and accounts for a larger part of the health insurance budget, was designated as a major disease. Hence, pulmonary hypertension drugs are evaluated only in terms of their clinical usefulness, and general hypertension drugs are evaluated in terms of both their clinical usefulness and cost-effectiveness.
Drugs having more than two indications are evaluated in the efficacy groups into which they fall. However, a price reduction is applied a maximum of two times. In other words, if a drug having three indications of hypertension, heart failure, and renal failure was evaluated two times for hypertension and heart failure efficacy groups and its price was reduced two times according to the results of those evaluations, it would not be evaluated as part of the renal failure efficacy group.
The evaluation criteria for clinical usefulness are shown in Table 3. Drugs are considered as clinically useful if they meet any one of the three requirements in grade A, such as a reference in a textbook, a recommendation in clinical practice guidelines, or a listing on the World Health Organization list of essential medicines. If none of the grade A requirements is met, all of the three requirements in grade B have to be met for a drug to be recognized as clinically useful, that is, a recommendation by related academia, special merits recognized by the DREC, and current usage in the countries grouped under the rubric "advanced 7 countries": United States, United Kingdom, Germany, France, Switzerland, Italy, and Japan. Drugs lacking clinical usefulness that are rejected in both grade A and grade B are delisted, whereas the others proceed to the next step.
Next, alternative groups within which each drug can be substituted with each other are set, and the daily costs of the drugs estimated from the unit price and daily dose are compared within the alternative groups. If the daily cost of a certain drug belongs to the bottom 25%, which is a criterion arbitrarily determined by the government, the drug is recognized as a relatively low-price drug and can stay on the reimbursement list without an additional economic evaluation. The rest of the drugs are evaluated in terms of their cost-effectiveness. In this evaluation, if the drugs are judged to be similar in terms of clinical effectiveness, a cost-minimization analysis is performed. If not, a cost-effectiveness or cost-utility analysis is done [11] . • Three subscribers, three providers, and two public servants
In the reevaluation of hypertension drugs, only 1 among 1226 items was delisted because of lack of clinical usefulness. In the evaluation of clinical effectiveness, not all hypertension drugs are clearly different in terms of proxy outcomes (systolic blood pressure, diastolic blood pressure) and final outcomes (all-cause mortality, cardiovascular mortality, cardiovascular morbidity). Therefore, the prices of hypertension drugs would have to be reduced to the lowest level if a cost-minimization principle is applied. It can be, however, problematic to select the lowest price as the reference price. First of all, the value of drugs does not correspond to the price because their price was set without strict criteria before the positive list system. Second, because drugs newly introduced for reimbursement cannot be listed at a price higher than those of already listed drugs with the same ingredients in Korea, local companies have emerged to deter rival companies from entering the market; local companies list drugs for reimbursement, which they have no intention of selling, at a very low price. For these reasons, the reference price was suggested as a band rather than a fixed price in hypertension drug evaluation. However, it became invalid after all because the delisting policy was changed to an "acrossthe-board" plan.
Barriers in the process
As mentioned previously, the pilot evaluation and subsequent evaluations were delayed much more than planned, revealing many problems [7, 8] . The problems most frequently raised by pharmaceutical companies were the transparency of the evaluation process, the evaluation methodology, and the serious impact on the pharmaceutical industry due to price reduction.
It is true that there were some unclear parts in the process, such as the selection of DREC members by ambiguous criteria and keeping the meeting minutes confidential. The composition of the DREC membership made it difficult for the opinions of consumers to be reflected fully. In addition, scientific disputes among stakeholders continued even after the end of the evaluation. In the hypertension drug evaluation, which ended in February of 2010, there was an opportunity in March of 2010 for relevant interest groups to appeal the evaluation results, and numerous objections about the selection of target patient, classification of an alternative group, and analysis method were raised. The interest group even went so far as to request a reevaluation of hypertension drugs by other researchers. To these stakeholders' claims, how- ever, the government adopted a non-neutral attitude and was biased toward the opinions of the pharmaceutical industry, holding two unscheduled hearings and a panel discussion only for the pharmaceutical industry. It even deviated from the determined process, such as extending the appeal period from 30 to 60 days. As a result, the actual price reduction for hyperlipidemia drugs was In fact, the dominant view from the beginning was that the on-schedule reevaluation would be impossible because of the nature of the system. First, the economic evaluation itself is a timeconsuming job. It is almost impossible to conduct the reevaluation comparing long-term outcomes of all drugs of one efficacy group within 1 year, especially in the case of drugs for chronic disease. Second, the infrastructure for the implementation of large-scale economic evaluations in Korea was insufficient.
The government judged from the two previous experiences (i.e., hyperlipidemia and hypertension drug evaluations) that finding a methodology with which all interest groups could agree was impossible, and if a reevaluation project is implemented at such a speed, it would not be finalized until 2020, making budget-saving claims dubious. In addition, the Ministry of Strategy and Finance strongly requested an across-the-board price reduction to save the national health insurance from financial deficit as soon as possible.
Eventually, the evaluation framework was changed totally from an economic evaluation to an across-the-board price reduction so as to finish the reevaluation project for listed drugs as soon as possible and remove the administrative burden placed on all stakeholders and on the government.
Change from an Economic Evaluation to an Acrossthe-Board Price Reduction
Amendments
The government suggested an "across-the-board price reduction" plan that was very different from the initial plan. Its specific contents are specified in Table 4 [12] . The biggest alterations from the original plan were that delisting should be determined mainly not by economic evaluations but by the criterion of meeting 80% of the highest price among drugs having identical ingredients, type, and dose (hereafter referred to as identical medicine). In other words, drugs whose price was above the 80% level were to be removed from the reimbursement list but could be retained if the pharmaceutical company voluntarily reduced the drug price to 80% or lower; in this case, the reduction could be spread evenly over 3 years, up to 7%, 14%, and more than 14% for the first, second, and third years, respectively. This criterion is not to be applied to the following: essential drugs (ban-on-delisting drugs and orphan drugs), drugs with valid patent, incrementally modified drugs without generic drugs, and drugs listed before the implementation of the DERP, whose price was reduced to 80% of the level of the original price because of the listing of a generic drug, which is also one clause of the DERP.
The rationale for the 80% criterion suggested by the government was as follows: The main targets of the delisting policy are the drugs listed before the DERP, and prices of drugs listed after the DERP are to be reduced to the 80% level when a generic drug with the same ingredients is listed for reimbursement. Therefore, the government view was that 80% would be a reasonable criterion for fairness between drugs listed before and after the DERP.
The government planned to finish the evaluation project of listed drugs with this changed plan by the latter half of 2011 and forecasted annual savings of 836.2 billion Korean won (approximately US $771 million or €543 million) in national health insurance finance. This was the amount calculated assuming that the drug price reductions for 47 efficacy groups would be applied to drug expenditures in 2009.
History of decision making in changing plan
On July 16, 2010, an amendment of the reevaluation of listed drugs was proposed under the name "reevaluation plan of listed drugs" on the agenda of the HIPRC. This plan was adopted by a majority of the HIPRC subcommittee on July 20, 2010. On that date, representatives from provider groups, subscriber groups, and public institutions participated in voting. Finally, only the Korea Confederation of Trade Unions (KCTU) refused to agree. The composition of the HIPRC is shown in Table 2 . In the composition scheme, the vice minister of Health and Welfare automatically becomes the Table 4 -Government's amendments for a reevaluation of listed drugs.
Price adjustment
• First, drugs with insufficient clinical usefulness will be excluded from the reimbursement list.
• In the next step, relatively low-price drugs belonging to bottom 33% in daily cost will be retained on the reimbursement list without a reevaluation process.
• Among drugs not belonging to the low-price drugs category, drugs in the top 20% in daily cost within the group of identical medicines (drug groups with the same ingredients, type, and dose) will be excluded from the reimbursement list. However, if the pharmaceutical company reduces the drug's price voluntarily to the 80% or lower level within the group of identical medicines, the drug can be retained on the reimbursement list. This 80% level is based on the rationale of fairness. In other words, in the existing system, the original drug listed after the introduction of the DERP is required to reduce its price to the 80% level when a generic drug with the same ingredients is listed. Because the targets of the reevaluation of listed drugs are those listed before the implementation of the DERP, this will ensure no discrimination between drugs listed before and after the DERP. If the 80% level within the group of identical medicines is lower than the relatively low-price criteria, relatively low-price criteria will be applied.
Target of reevaluation
• The reevaluation targets are original drugs for which generic drugs with the same ingredients are available and that were listed before the DERP enforcement (excluding essential drugs such as ban-on-delisting drugs, rare drugs, and patented drugs). Second, drugs listed within the group of identical medicines before the DERP enforcement and those whose patent is still in force shall be evaluated as soon as the patent expires. In addition, drugs listed solely as identical medicines shall be included if the patent has expired.
• Although a drug was listed before the DERP enforcement, if its price was reduced to the 80% level because of the listing of a generic drug with identical ingredients after the DERP enforcement, the drug shall be excluded from the target list.
Price reducing method
When a pharmaceutical company voluntarily wants to reduce drug prices to 80% or to a lower level, a reduction can be done gradually over 3 years (to the 7% level in the first year, the 14% level in the second year, and greater than the 14% level in the third year).
DERP, Drug Expenditure Rationalization Plan.
HIPRC chair, and 24 committee members are composed of representatives of eight subscriber groups, eight provider groups, and eight public institutions. The KCTU is a consumer-oriented organization that plays a pivotal role in the network of civic groups and trade unions. It also exercises political leverage as a leader of the civic groups, having many supporters and being strongly connected with the Democratic Party.
After the changed plan proposed by the government was passed by a majority of votes in the subcommittee, despite KCTU's objection, the KCTU discussed this issue with civic groups through two urgently arranged conferences and submitted an independent plan on July 22 that was different from the government's plan (Table 5 ). The plan suggested jointly by the KCTU and the civic groups clearly stated their objection to the government's plan in principle. They requested delisting the drugs that did not satisfy the reimbursement criteria rather than allowing price reduction, and applying price reduction regardless of patent validity, and all at once rather than in phases, if at all. In addition, they asked the government to present evidence supporting its estimation that the government's amendments could achieve savings of 836.2 billion Koran won (US $771 million or €543 million) in health insurance finance. Both the plan proposed by the government and the KCTU/civic groups plan were referred to the HIPRC plenary meeting held on July 28, 2010. Finally, the government's plan was put to the vote and passed.
Eventually, the changed plan was applied to hypertension drugs, the second efficacy group in the reevaluation project of the listed drug on which no political action had taken place since the completion of the evaluation study, and its price cut was implemented in January of 2011. The evaluation studies for five efficacy groups that had been in progress since the beginning in November of 2009 also ended uncompleted in August of 2010. The government had an action schedule to cut the price of these five efficacy groups in July of 2011, and the price of the remaining 41 efficacy groups by January of 2011 according to the changed plan.
Responses from stakeholders
Pharmaceutical industry
It is expected that the changed plan may cause serious damage to middle-and high-ranking domestic pharmaceutical companies as well as major multinational ones, more so than it will impact smaller companies. Although the government suggested the goal of fairer pricing between drugs listed before and after the DERP as a rationale for the criterion of the 80% price level, the prices of many drugs listed before the DERP were already lowered several times because of other systems, such as 1) the drug price readjustment system that readjusts drug prices triennially to reflect changes in drug price in advanced 7 countries and 2) the drug price monitoring system that investigates the actual transaction price three or four times every year and reduces the drug prices to the actual price level [13] . In some cases, more than half of the price may be reduced if both the price readjustment system and the reevaluation system of listed drugs are applied. Therefore, pharmaceutical companies have insisted that it would be more reasonable to apply a 20% price reduction not on the current price but on the initially listed price.
In fact, opinions even within multinational pharmaceutical companies have been varied [14] . Some companies have argued that there is no justification or reason to accept the across-theboard price reduction, insisting that they only wanted to retry the hypertension drug evaluation by using other methodology rather than denying the economic evaluation principle completely. Some companies supported the newly changed plan even though it was not fully satisfactory. Other pharmaceutical companies did not take a clear stance, saying that a precise estimation of profit and loss is required because the evaluations of some efficacy groups that in the original plan had been planned for 2012 or later were moved forward to 2011 in the changed plan.
There were also differing opinions among domestic pharmaceutical companies. They, however, converged toward the opinion that it seems to be better to accept the plan, because its impact would be much less than that of the original plan, given that prices of hyperlipidemia drugs were reduced by a maximum of 37.5% and that hypertension drug prices should be reduced by a maximum of 80% according to the cost-minimization principle.
Taken as a whole, the pharmaceutical industry seemed not to oppose the across-the-board price reduction plan because it would be much less severe and would, in fact, decrease the burden on the company considerably [15] . A simulation analysis with the top 100 most frequently prescribed hypertension drugs showed that only 26 products were subjected to a price reduction by the government's changed plan and that most drugs in the angiotensin receptor blocker or angiotensin-converting enzyme inhibitor class with the highest prices among hypertension drugs were excluded because most of them have valid patents. Table 4 .
• Object to the government's plan.
• Request detailed evidence about the cost-savings effect in insurance finance.
• Request for abiding by HIPRC decisions made in 2009 (delisting drugs not satisfying the reimbursement criteria, not offering an opportunity for a price reduction, and a price reduction done at once, not over 3 years).
Reevaluation target
• Drugs listed before the DERP enforcement with generic drugs of the same ingredients listed.
• Identical to the government's plan.
Exempted from reevaluation
• Essential drugs (ban-on-delisting drugs, rare drugs, etc.).
• Apply a price reduction regardless of the validity of a patent.
• Drugs with valid patent (including incrementally modified drugs).
• Clarify the reevaluation schedule and start plan as soon as possible.
• Drugs whose price is reduced to the 80% level because of generic listing after the DERP enforcement. 
Medical profession
The Korean Medical Association expressed its disagreement with the changed plan, as it did in the pilot reevaluation [16] . It did not, however, suggest any alternative plan or take any strong action, only insisting that other methodology needs to be developed because objectivity and reliability are not guaranteed in an economic evaluation. It also insisted that if the across-the-board price reduction is implemented, the portion saved through it should be used to raise physician fees.
Civic groups
Civic groups expressed their strong objection practically, such as by submitting a separate proposal together with the KCTU against the government's plan.
On July 28, 2010, the day of the HIPRC plenary meeting, they held a press conference to urge the government to abandon the changed plan. The reasons for their objection were as follows: first, it severed the agreements based on the experience of the pilot evaluation, which suggested that the number of drugs listed for reimbursement, rather than prices, should be reduced and that lowering the price of the drugs should be done all at one time rather than in a progressive manner. Second, the cost-saving effect of the government's plan was doubtful. Last, giving up reevaluation based on economic analysis and turning to across-theboard price reduction was viewed as being unsustainable and disconnected with other policies of the DERP [17] .
The civic groups also strongly expressed their view that if the changed plan was enforced without their agreement, they would resist its implementation by using all available actions, such as requesting an audit of the MOHW to the Board of Audit and Inspection, administrative litigation, and requesting opening of the background data on the cost-saving effect of the changed plan [18] . They focused, however, on accomplishing their plan later (Table 5) , which was proposed jointly with the KCTU, rather than clinging to an overall objection to the government's plan, considering that too much persistence on principle and cause would attain nothing.
Challenges to the Delisting Policy
Currently, many countries such as Australia and Spain have been trying to advance disinvestment issues and have put these issues on their national agenda. As part of this effort, they tried developing guidelines and identifying key challenges to search for the best avenues [19 -21] . In Australia, five challenges were identified: a lack of resources; lack of reliable administrative mechanism; lack of published evidence; political, clinical, and social challenges; and inadequate resources to support a research agenda [19] . Some, but not all, of these problems also exist in Korea. In the delisting policy of Korea, there were problems such as the lack of a reliable administrative mechanism and of published evidence studies, as well as clinical and social challenges, whereas resources for policy implementation were supported without dispute.
The following key lessons learned from experiencing challenges can be helpful for other countries (Table 6 ).
Managerial ability of the government
There were a few reasons that led the government to change the framework for the reevaluation of listed drugs from cost-effectiveness to an across-the-board price reduction. The most serious among them was the delayed schedule of the evaluation project. The government wanted to alleviate the burden on both the pharmaceutical companies and themselves by finishing projects via an across-the-board price reduction and realizing rational drug expenditures as soon as possible. It is true that the delay in the evaluation schedule was partly due to the nature of the study itself. The lack of government's managerial ability, however, was to blame as well-for example, its excessive consideration for the stakeholders' interests. In addition, the evaluation periods were gradually being shortened based on the experience gained during the hyperlipidemia and the hypertension drug evaluations. Therefore, it is assumed that the reevaluation project for the remaining efficacy groups would have been completed in a much shorter time compared with the time needed up to that point.
The government also insisted that an across-the-board price reduction could raise the possibility for concerned interested parties to predict the impact of the policy and make it easier to comply with it. In other words, in an economic evaluation, it was difficult for a pharmaceutical company to predict the result of an analysis and adjust its drug price in advance so as not to have the drug delisted from reimbursement. It is certain that pharmaceutical companies, however, would always respond negatively to any reevaluation method because the reevaluation itself would certainly not increase their profit. In addition, because the original purpose of the reevaluation for the listed drugs was to reduce the number of listed drugs rather than lower the prices, making it easier for a pharmaceutical company to predict the result of an evaluation and giving it a chance to reduce its drug price so as not to be dropped out of the reimbursement list would be at odds with the original purpose of the reevaluation project.
The government's leadership and strong will are very important for the successful implementation of a policy. In fact, in the implementation of the delisting policy, it seemed that the awareness of the crisis in health insurance finance and the necessity of drug expenditure control were raised sufficiently, and agenda setting such as a delisting policy and a positive listing system for new drugs was proper. The government, however, showed a lack of managerial ability, and its will was weakened in the actual implementation step, partly because of the conservative political ideology of the ruling party. In addition, there was no strong network among groups advocating the policy. If the government had handled this challenge more intelligently and decisively with a reliable administrative mechanism, a sustainable framework for a delisting policy applicable in the future may have been established.
Methodology of the delisting policy
The government's changed plan compares the costs only within drugs having an identical type, ingredient, and dose (i.e., identical medicine), whereas an economic evaluation compares both the effectiveness and the cost of all the drugs in the same efficacy group. In the evaluation of the hypertension drugs, drugs within the same classes such as beta-blockers and angiotensin receptor blockers were first compared with each other in terms of effectiveness. After it was concluded that there were no clear differences in Table 6 -Key lessons for other countries.
1. Policymakers and executors need to clearly recognize the objective of policy and the function of its tool. In the reevaluation of the listed drugs, they should have realized that economic evaluation is not merely for price reduction but for rational drug expenditure. 2. The policy tool should be sustainable and rational and can be publicly supported. In addition, it should be practical, which means that it cannot be too academic or scientific and should be easy to implement. 3. Balance between harmonization with stakeholders and sticking to the principle is very important especially when policy is involved with many interest groups. 4. It is better for policy to be incremental, considering the experiences of past policies. 5. Policy should be based on evidence that is as precise and detailed as possible.
effectiveness between drugs within the same class, the difference in effectiveness between the classes was evaluated. In this manner, all the drugs indicated for hypertension were compared with each other. Although drugs deficient in clinical usefulness are supposed to be delisted regardless of their cost in the first step in the across-the-board price reduction also, it can be said that the changed plan is mainly focused on cost rather than on clinical effectiveness, as the number of excluded items in the clinical usefulness review phase would be extremely small, given the fact that in the hypertension drug evaluations, only 1 item among 1226 items was delisted because of the lack of clinical usefulness. In addition, the across-the-board price reduction scheme is not consistent with the current new drug listing system. Since the introduction of the positive list system, the listing and pricing of a new drug is based on cost-effectiveness analysis, and a comparator in the economic evaluation is selected not only within identical medicines but also within all possible scope, including even nonintervention options.
Of course, there may be a need for such a mechanical price reduction in the early stages of evaluation. However, relying on an across-the-board price reduction scheme as the only methodology would be risky and will eventually lose its overall consistency as a standard for drug reimbursement.
A delisting policy based on economic evaluations should be the priority instead of annulling all the studies underway and detouring toward poorly grounded, across-the-board price reductions merely for convenience and for time considerations. It is important to construct a basic frame based on reliable theory and methodology that can be used for a long time, because health insurance itself is not merely a short-term system. Considering the context in Korea, where a considerable number of drugs are already listed compared with the number in other countries, an economic evaluation for listed drugs needs to be designed somewhat simply and feasibly for practical application to policy, unlike that for the listing of a new drug.
Competitiveness of local pharmaceutical companies in the international market
Korean pharmaceutical companies tend to focus on the production, distribution, and sales of generic drugs rather than developing new drugs on their own through research and development. In addition, it is commonly recognized that the negative list system has been deteriorating the competitiveness of local companies in the international market. Local companies could enjoy a good profit for a long time because they could list their drug for reimbursement very easily and obtain high prices relative to their production cost under the negative list system. Rather than investing in research and development to improve drug quality or develop new drugs, however, many companies spent part of this profit on unethical promotion intended to induce prescription of their products [22, 23] . According to a press release of the Fair Trade Commission, a central administrative organization under the authority of the prime minister, as much as 20% of the total sales of local companies were estimated to have been spent on this type of promotion [24] .
In the government's changed plan, it is assumed that generic drugs have little impact because most drugs belonging to the top 80% groups are original drugs. For this reason, a delisting policy based on a cost-effectiveness analysis could be an effective instrument to enhance the quality and competitiveness of local producers by giving them opportunities to change their business behavior in the market. The government, however, gave up this chance by changing the plan.
Public support for the government policy
Subscriber groups and civic groups recognized the government's decision to forego the original delisting policy as a stereotype of the so-called capture theory in policy-making and became much less supportive of the government's health-care policy thereafter. The opposition party in the National Assembly discussed this issue in a public conference and criticized the government's inability to implement the policy. The Korean national TV network broadcast a program about the delisting policy in January of 2011 and pointed out the government's failure in a pharmaceutical policy. The Korean Association of Health Technology Assessment held a conference regarding the delisting policy and opened the debate to pros and cons. Through a series of discussions, the government seemed to lose public support and reliability, which has made the government's leadership less effective.
Conclusions
South Korea is the first country in Asia to develop a pharmacoeconomic evaluation guideline and apply cost-effectiveness criteria to reimbursement decision making through pharmaceutical policy reform. Therefore, we have experienced many trials and errors and have many issues to be addressed, such as the lack of domestic clinical data, restrictions in accessibility to cost data, and the noncompliance of stakeholders.
While a new drug listing system has been established in spite of these difficulties, the delisting policy has not gone smoothly. Much resistance has been expressed by stakeholders, and the government did not cope well with these issues. Eventually, it turned to an across-the-board price reduction plan, annulling all the evaluation studies in progress. The pharmaceutical policy reform in South Korea failed in that it was abandoned even before being properly implemented, and the policy changed by the government is not expected to have a significant cost-saving impact on the health insurance budget, not giving any motivation to local companies to strengthen their competitiveness.
If an attempt is made to identify a few opportunities and realize them, however, there is still the potential for financial savings through a delisting policy. First, the government needs to implement a drugs delisting policy with a wide and far-sighted scope, rather than focusing only on visible short-term performance. To do this, it is rational to conduct a policy under an economic evaluation principle. The concept of cost-effectiveness would be well founded and sound as a tool for the delisting policy in spite of its limitations and difficulties, as long as its methodology is designed more practically. Second, if the ultimate purpose of the delisting policy is financial savings through drug price reductions or by downsizing the reimbursement drug list, a policy tool for such a purpose should be operated separately from an economic evaluation. Economic evaluations are not a tool for merely reducing the budget but for allocating health resources efficiently. It is undeniable that all the confusion was caused because of the distorted understanding of an economic evaluation by those concerned, including government officials, because the positive list system using economic evaluations was introduced at the time when the deficit in the insurance budget was a major issue, with excessive drug expenditures blamed for it. Finally, a methodology based on economic evaluations for drug pricing should be designed from a greater number and variety of angles, that is, reflection of an equity factor that lacks in economic evaluations and social acceptability.
In 2010, the Korean national health insurance showed the largest deficit ever, reaching approximately 1.3 trillion Korean won (approximately US $1.2 billion or €844 million). Uncontrolled drug expenditures due to the failed delisting policy is one of the factors for this crisis. This could, however, actually present opportunities for reconsidering the delisting policy, because this crisis creates further pressure for drug expenditure containment, finally leading to the stable management of health insurance finance if all the opportunities explained previously are realized together.
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